The role of taxanes in the management of bladder cancer

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

Transitional cell carcinoma of the bladder is a chemosensitive neoplasm. Whereas the MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimen was long considered the standard of care for patients with advanced disease, the evaluation of newer agents with retained activity and improved tolerability has been the focus of much investigation over the past decade. Among the most important of these newer agents are taxanes. Whereas taxane-containing regimens have not yet been shown to improve the survival of patients with transitional cell carcinoma in randomized trials, ongoing phase III trials will further define the role of these agents in both the perioperative and advanced disease settings.

Original languageEnglish
Pages (from-to)792-798
Number of pages7
JournalOncologist
Volume10
Issue number10
DOIs
StatePublished - Nov 2005
Externally publishedYes

Keywords

  • Bladder cancer
  • Chemotherapy
  • Docetaxel
  • Paclitaxel

Fingerprint

Dive into the research topics of 'The role of taxanes in the management of bladder cancer'. Together they form a unique fingerprint.

Cite this